Grove Bank & Trust’s Royalty Pharma RPRX Stock Holding History

Grove Bank & Trust’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$48	–	916
2026 Q1	$48	Buy	+1	New	+$44	﹤0.01%	851

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Grove Bank & Trust's RPRX Position: Q2 2026 in Review

Grove Bank & Trust sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 1 share — an estimated $48 sold.

Grove Bank & Trust first reported a position in RPRX in Q1 2026 and held it in 1 quarter. The position peaked at $48 in Q1 2026. 641 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Grove Bank & Trust reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
Grove Bank & Trust sold 1 Royalty Pharma share in Q2 2026, an estimated $48.
Grove Bank & Trust first reported a position in Royalty Pharma in Q1 2026 and held it in 1 quarter.
Grove Bank & Trust's Royalty Pharma position peaked at $48 in Q1 2026.
641 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Grove Bank & Trust's 13F filing for Q2 2026, filed 7 Jul 2026.